| European Case Law Identifier: | ECLI:EP:BA:2017:R000715.20170515 | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Date of decision: | 15 May 2017 | ||||||||
| Case number: | R 0007/15 | ||||||||
| Petition for review of: | T 1651/11 | ||||||||
| Application number: | 03721414.5 | ||||||||
| IPC class: | A61K 31/4035 C07D 209/48 C07C 317/28 A61P 35/00 |
||||||||
| Language of proceedings: | EN | ||||||||
| Distribution: | B | ||||||||
| Download and more information: |
|
||||||||
| Title of application: | (+)-2-[1-(3-ETHOXY-4-METHOXYPHENYL)-2-METHYLSULFONYLETHYL]-4-ACETYLAMINOISOINDOLINE-1,3-DIONE FOR USE IN TREATING PSORIASIS BY ORAL ADMINISTRATION | ||||||||
| Applicant name: | CELGENE CORPORATION | ||||||||
| Opponent name: | Ratiopharm GmbH | ||||||||
| Board: | EBA | ||||||||
| Headnote: | - | ||||||||
| Relevant legal provisions: |
|
||||||||
| Keywords: | Violation of the right to be heard, no | ||||||||
| Catchwords: |
- |
||||||||
| Cited decisions: |
|
||||||||
| Citing decisions: |
|
||||||||
Source: http://www.epo.org/law-practice/case-law-appeals/recent/r150007eu1.html
Date retrieved: 17 May 2021